| __timestamp | MiMedx Group, Inc. | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 90480000 | 59644696 |
| Thursday, January 1, 2015 | 133384000 | 79541000 |
| Friday, January 1, 2016 | 179997000 | 98015000 |
| Sunday, January 1, 2017 | 220119000 | 103958000 |
| Monday, January 1, 2018 | 258528000 | 103654000 |
| Tuesday, January 1, 2019 | 198205000 | 128951000 |
| Wednesday, January 1, 2020 | 181022000 | 135799000 |
| Friday, January 1, 2021 | 198359000 | 149883000 |
| Saturday, January 1, 2022 | 208789000 | 220206000 |
| Sunday, January 1, 2023 | 211124000 | 265542000 |
In pursuit of knowledge
In the competitive world of biotechnology, managing costs is crucial for success. This chart compares the Selling, General, and Administrative (SG&A) expenses of Travere Therapeutics, Inc. and MiMedx Group, Inc. from 2014 to 2023. Over this period, MiMedx Group's SG&A expenses grew by approximately 133%, peaking in 2018. Meanwhile, Travere Therapeutics saw a staggering 345% increase, with a notable surge in 2023.
Understanding these trends provides valuable insights into each company's strategic priorities and financial health, offering a glimpse into their operational strategies in the ever-evolving biotech landscape.
Comparing SG&A Expenses: Merck & Co., Inc. vs MiMedx Group, Inc. Trends and Insights
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs Travere Therapeutics, Inc.
Selling, General, and Administrative Costs: United Therapeutics Corporation vs MiMedx Group, Inc.
SG&A Efficiency Analysis: Comparing Summit Therapeutics Inc. and Travere Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and MiMedx Group, Inc.
SG&A Efficiency Analysis: Comparing Corcept Therapeutics Incorporated and Travere Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
Selling, General, and Administrative Costs: Verona Pharma plc vs Travere Therapeutics, Inc.
Breaking Down SG&A Expenses: PTC Therapeutics, Inc. vs MiMedx Group, Inc.
SG&A Efficiency Analysis: Comparing Mesoblast Limited and Travere Therapeutics, Inc.
Breaking Down SG&A Expenses: MannKind Corporation vs Travere Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Amphastar Pharmaceuticals, Inc. and Travere Therapeutics, Inc.